Logo
Login

Company Executives

$ Management Team

Mr. Daniel Lynch

Independent Chairman of the Board

Age 65
Compensation $545.1K USD
Sex Male

Mr. Saqib Islam

Chief Executive Officer

Director

Age 54
Compensation $18.35M USD
Sex Male

Mr. Francis Perier

Chief Financial Officer

Age 64
Compensation $3.740M USD
Sex Male

Dr. Badreddin Edris

Chief Operating Officer

Age 37
Compensation $6.739M USD
Sex Male

Mr. Daniel Pichl

Chief People Officer

Age 41
Compensation $2.315M USD
Sex Male

Dr. Tai-an Lin

Chief Scientific Officer

Age 61
Compensation -
Sex Male

Mr. Herschel Weinstein

General Counsel

Secretary

Age 68
Compensation $2.799M USD
Sex Male

Mr. Bhavesh Ashar

Chief Commercial Officer

Age 58
Compensation $4.943M USD
Sex Male

Dr. James Cassidy

Chief Medical Officer

Age 65
Compensation $4.209M USD
Sex Male

Board of Directors

From the proxy statement filed Apr 4, 2025
Directors
7
serving now
Independent
6 of 7
stated in the proxy
Average tenure
5.6 years
from year joined
CEO also chairs the board
No
Daniel S. Lynch
Director Age On board Independent Committees Other public boards 2024 pay Source
Alan Fuhrman
68 2019
6 years
 Independent
Audit and Compliance Committee · Chair
Esperion Therapeutics, Inc. $625,239
Julie Hambleton
67 2020
5 years
 Independent
Audit and Compliance Committee
IGM Biosciences, Inc. $625,239
Daniel S. Lynch
Board chair
 66 2016
9 years
 Independent None stated None stated $650,239
Saqib Islam
CEO
 55 2018
7 years
 Not independent None stated Passage Bio, Inc. Paid as CEO
Carlos Albán
62 2022
3 years
 Independent
Compensation Committee
Solventum Corporation $612,739
Freda Lewis-Hall
70 2017
8 years
 Independent
Audit and Compliance Committee
Exact Sciences Corporation Not stated
Martin Mackay
68 2024
1 year
 Independent
Compensation Committee
Novo Nordisk Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

No related-party transactions disclosed

The proxy filed Apr 4, 2025 describes a review policy but reports no transactions.

Read the policy in the proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans